Notice of Results

RNS Number : 3393W

Novacyt S.A.

17 April 2023

 

 

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

 

Notice of Full Year 2022 Results and Investor Presentation

 

Paris, France and Eastleigh, UK – 17 April 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2022 on Thursday, 27 April 2023.Investor webinarAn investor webinar presentation by James McCarthy, Acting Chief Executive Officer, and Steve Gibson, Group Finance Director, will take place at 12.00pm BST on Thursday, 27 April 2023.The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.Investors can sign up to Investor Meet Company for free and add to meet NOVACYT S.A. via:https://www.investormeetcompany.com/novacyt-sa/register-investorInvestors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

 

– End –

Contacts

Novacyt SAJames Wakefield, Non-Executive ChairmanJames McCarthy, Acting Chief Executive Officer+44 (0)1276 600081SP Angel Corporate Finance LLP (Nominated Adviser and Broker)Matthew Johnson / Charlie Bouverat (Corporate Finance)Vadim Alexandre / Rob Rees (Corporate Broking)+44 (0)20 3470 0470Numis (Joint Broker)James Black / Freddie Barnfield / Duncan Monteith+44 (0)20 7260 1000Allegra Finance (French Listing Sponsor)Rémi Durgetto / Yannick Petit+33 (1) 42 22 10 10 [email protected]; [email protected]Walbrook PRPaul McManus/ Stephanie Cuthbert/ Anna Dunphy+44 (0)20 7933 8780 [email protected]

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world’s most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing. 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange’s AIM market (“NCYT”) and on the Paris Stock Exchange Euronext Growth (“ALNOV”).

 

For more information, please refer to the website: www.novacyt.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.